1	Creation of a Shortened Version of the of the Sleep
2	Disorders Questionnaire (SDQ)
3	
4 5 6	Short Title: Short version of SDQ
7	Kathleen Biard ¹ ¶, Joseph De Koninck ¹ ¶ ² , Alan B. Douglass ² ¶ ^{3*}
8 9 10 11 12 13 14 15 16 17 18 19 20	 ¹ School of Psychology, Faculty of Social Sciences, University of Ottawa, Ottawa, Ontario, Canada ² University of Ottawa Institute of Mental Health Research at the Royal Ottawa Mental Health Center, Ottawa, Ontario, Canada ³ Psychiatry Department, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
21 22	*Corresponding author (ORCID ID 0001-6837-9799)
23 24	Email: alan.douglass@theroyal.ca (ABD)
25 26 27 28 29 30	[¶] These authors contributed equally to this work

31 Funding:

32	A Canada Graduate Scholarship (CGS) from the Natural Sciences and Engineering Research
33	Council (NSERC) supported the PhD studies of Dr. Biard and her analysis of the data.
34	
35	Competing Interests:
36	Drs. Biard and De Koninck declare no competing interests
37	
38	Dr. Douglass claims copyright of the resulting SDQ-2 questionnaire and may profit from its
39	future commercialization. He is also a paid consultant to the Ottawa Police Association, which
40	is sponsoring a validation study of the SDQ-2.
41	
42	
43	
44	
45	
46	
47	
48	

49 Abstract:

50

The 176-item Sleep Disorders Questionnaire (SDQ) was initially developed using canonical 51 discriminant function analysis on 4 groups of sleep disorder patients, but it was never studied by 52 factor analysis in its entirety. Several authors have criticized 2 of its subscales as being 53 confounded with each other, and its narcolepsy scale as substantially over-diagnosing 54 narcolepsy. This study describes its first exploratory factor analysis (EFA), the intent of which 55 was to reassess item membership on the 4 existing subscales and to derive new scales to improve 56 differential diagnosis between patient groups. It was also hoped that EFA could reduce the total 57 58 number of questions, to increase speed of completion. The EFA was performed on the anonymized SDO results from a retrospective review of the charts of 2131 persons from 7 sleep 59 disorders clinics and research centers. Factors were assessed via scree plots and eigenvalues. 60 61 The EFA identified four main factors: insomnia, daytime sleepiness, substance use, and sleepdisordered breathing. The insomnia factor had 3 subfactors: psychological symptoms of 62 insomnia, subjective description of insomnia, and insomnia due to periodic limb movements. 63 The sleepiness factor had two subfactors: davtime sleepiness and neurological symptoms of 64 narcolepsy. The novel substance use factor was homogeneous, as was the sleep-disordered 65 66 breathing factor. Importantly, the EFA reassigned items from the original SDQ's NAR, PSY, and PLM subscales to five of the new subscales. The Sleep Apnea (SA) subscale emerged 67 mostly unchanged. The 7 resulting factors comprised only 66 items of the original 176-item 68 69 SDO. These results have allowed the creation of a new shorter questionnaire, to be called the SDQ-2. External validation of the SDQ-2 is currently underway. It will likely prove to be a 70

- ⁷¹ superior differential diagnostic instrument for sleep disorders clinics, compared to the original
- 72 SDQ.

73 List of Abbreviations

- 74 Berlin Questionnaire: screening questionnaire for sleep apnea
- 75 BMI: Body Mass Index (kg/m²)
- 76 EFA: exploratory factor analysis
- 77 ESS: Epworth Sleepiness Scale
- 78 GAD-7: Generalized Anxiety Disorder, 7-item scale
- 79 MIES: Moral Injury Events Scale
- 80 NAR, PSY, PLM, SA: subscales of the original SDQ
- 81 OSA: obstructive sleep apnea
- 82 PCL-5: PTSD Checklist for DSM-5
- 83 PHQ-9: Patient Health Questionnaire (depression)
- 84 PLM: periodic limb movements
- 85 PSQI: Pittsburgh Sleep Quality Index
- 86 RLS: Restless Legs Syndrome
- 87 ROC: receiver operating characteristics (analysis)
- 88 SDB: sleep disordered breathing
- 89 SDQ: the original Sleep Disorders Questionnaire, 1994
- 90 SDQ-2: second edition of the SDQ, derived in the present paper
- 91 SQAW: Stanford University's Sleep Questionnaire and Assessment of Wakefulness
- 92 STOP-Bang: screening questionnaire for sleep apnea

- 93 TIA: transient ischemic attack
- 94 CAGE: alcohol screening questionnaire
- 95 ISI: Insomnia Severity Index

98 Introduction:

99	The aim of the original Sleep Disorders Questionnaire (SDQ) was to provide a self-report
100	tool to assess the risk of having one of several sleep disorders. It was developed between 1983
101	and 1994 by Douglass and colleagues[1] at Stanford University from their existing Sleep
102	Questionnaire and Assessment of Wakefulness (SQAW)[2]. The latter had been difficult to use
103	clinically due to its great length, over 800 items, and its many different response sets. SDQ
104	retained only 175 of its items, which were then grouped, simplified, re-worded, and all changed
105	to 5-point Likert scales. Body mass index (BMI) was added as the 176th item, to be entered by a
106	clinician.
107	SDQ items were deemed to have adequate face validity when assessed by three Stanford
108	sleep specialists, and were validated against polysomnographic diagnoses in a canonical
109	discriminant function analysis of 519 patients[1]. This resulted in four subscales characteristic of
110	patients with common sleep disorders (subscale name in brackets): narcolepsy (NAR), sleep
111	apnea (SA), periodic limb movement disorder (PLM) and sleep disturbance due to psychiatric
112	illness (PSY). Receiver Operating Characteristics (ROC) analysis for each subscale
113	demonstrated adequate sensitivity, specificity, and positive / negative predictive values. Item
114	test-retest reliability of the SDQ items was assessed by Pearson correlation over an interval of 3
115	to 4 months in 130 patients and 71 normal controls[3]; the range of correlation was from $r =$
116	0.308 to 0.985, mean $r^2 = 0.636$.
117	With its focus on diagnosis, SDQ differed from scales like the Pittsburgh Sleep Quality
118	Index (PSQI)[4], which focus on subjective descriptions of sleep that correlate most strongly
119	with psychological mood and anxiety questionnaires. Another focus of SDQ has been the
120	identification of sleep disorders that are co-morbid with other medical and psychiatric diagnoses.

This was exemplified by a study[5] using SDQ and the NoSAS questionnaire to look for sleep 121 apnea in patients with diagnosed depression. Similarly, a controlled study[6] showed significant 122 elevations of the PSY and PLM scales in patients with COPD. 123 Using the German translation of the SDQ, a study[7] of 3521 patients undergoing 124 polysomnography showed significant sex differences by ANOVA within the 4 SDQ scales, 125 126 which the authors postulated might explain the under-recognition of sleep-disordered breathing (SDB) in women. 127 A brief review of the literature regarding the 4 existing subscales of the SDQ and 128 problems with their usage is as follows: 129 **SDQ-PLM subscale:** A 2006 study of 4,901 Swiss pharmacy customers by 130 Schwegler[8] factor analyzed 45 items from the French and German translations of the SDQ. 131 Their goal was to confirm the uniqueness of the 4 original SDQ subscales and to use the Epworth 132 Sleepiness Scale[9] as an external validator. While their Cronbach's alpha coefficients for 133 134 subscale homogeneity were similar to those in the original SDO paper, they found that 60% of respondents scored above the originally-proposed pathological cut-off score of the PLM subscale 135 (which they called "RLS scale"). They also found that the SDQ-PSY subscale had Spearman 136 correlations of nearly 0.50 with both the PLM and NAR subscales, belying its intended purpose 137 of identifying sleep disturbance in patients with psychiatric illness. To date, few other papers 138 have reported use of the SDQ-PLM subscale. A validation by Valencia-Flores[10] found a 139 correlation (Spearman's rho = 0.59) between the SDQ-PLM subscale and the PLM index on 140 polysomnography in 14 patients with systemic lupus erythematosus. This subscale has also been 141 142 used to screen for causes of sleep problems in dementia patients[11]. Overall, SDQ's PLM

subscale appeared to be tapping into more general features of insomnia rather than those dueonly to true RLS/PLMD.

SDO-NAR subscale: This subscale was intended to be sensitive to the symptoms of 145 patients suffering narcolepsy-cataplexy (narcolepsy type 1), but it also proved to include items 146 that were endorsed by respondents who were sleepy due to other causes. Another surprise in the 147 Schwegler study[8] was that 10% of their respondents scored above the 90th percentile on the 148 NAR subscale. Since the population prevalence [12] of narcolepsy is less than 50/100,000, the 149 SDO-NAR subscale obviously grossly over-diagnosed narcolepsy. These results suggested that 150 the NAR subscale might be reflecting non-narcoleptic sleepiness in the general population, in 151 addition to neurological symptoms of narcolepsy. Unexpectedly, Parkinson Disease patients also 152 153 scored significantly higher on the NAR subscale than controls[13], although this was attributed to side-effects of their dopaminergic medications rather than to narcolepsy. 154

SDQ-SA subscale: Some papers refer to this as "SA-SDQ", but the preferred 155 acronym is "SDO-SA". Its diagnostic intent was similar to that of other obstructive sleep apnea 156 (OSA) questionnaires in the literature, such as the Berlin[14], STOP-Bang[15], NoSAS[16], and 157 158 the OSA50[17]. In contrast to these, however, the SDQ-SA did not require any physical measurements or interaction with a clinician. SA is the SDQ subscale most commonly reported 159 in the literature[18-21], likely due to its high sensitivity, specificity, PPV, and NPV when 160 161 compared[22] to other sleep apnea questionnaires. Recent meta-analyses and reviews[23-26] have also supported the diagnostic usefulness of the SA subscale. 162

A much larger Swiss pharmacy study[27] of nearly 200,000 persons employed the SDQSA (called "SAS" by the authors) along with the Epworth Sleepiness Scale (ESS) to predict

motor vehicle accidents due to sleepiness. They found that SDQ-SA subscale homogeneity by 165 Cronbach's alpha was again similar to the value in the original Douglass paper at rho = 0.74. 166 Malow[28] found that SDO-SA scores were significant predictors of ESS scores in 158 167 epilepsy patients, whereas anti-epileptic medication dose or seizure frequency were not. 168 Weatherwax^[29] suggested that the original cutoff scores for diagnosing OSA in the general 169 170 population should be lowered for epilepsy patients. The SDQ-SA subscale has also been used to identify OSA in patients with transient ischemic attacks (TIAs)[30-33] and in those with morbid 171 obesity[34]. 172

SDQ-PSY subscale: Scores on this subscale are high in hospitalized patients with 173 major mood disorders or psychosis, likely due to the insomnia and sleep fragmentation often 174 175 reported by these patients. It was partially validated [35] by correlation with the Carroll Depression Scale[36] in 44 patients diagnosed with Major Depressive Disorder (r = 0.70, p < 0.70176 0.0001). It also showed significant negative correlation with sleep efficiency on the 177 178 polysomnograms of these same patients (r = -0.30, p < 0.05). Brower[37] used this subscale to assess the subjective sleep complaints of 74 patients recovering from alcohol dependence in a 179 search for symptoms predictive of alcoholism relapse. Relapsers proved to have higher baseline 180 scores on the SDQ-PSY subscale than those who abstained over a follow-up period of 3-12181 months. Some authors, including Brower, have however argued that the SDQ-PSY subscale is 182 actually an insomnia subscale, based on their own studies [38,39]. In support, Sweere [40] 183 performed a cluster analysis on a Dutch translation of 89 items from the SDQ and found a clear 184 insomnia subscale in addition to 2 others that closely resembled the SDQ's SA and NAR 185 186 subscales.

Taken together, the above findings suggest that the use of SDQ in non-clinical populations sometimes substantially over-diagnoses sleep pathologies. They also imply that some SDQ subscales are confounded with each other, possibly due to items concerning insomnia appearing on more than one subscale. Some of these problems could also be due to the fact that the original SDQ scales were derived not by factor analysis but rather by canonical discriminant function analysis on responses from 4 polysomnographically-diagnosed groups of sleep disorder patients.

Over the past 35 years, SDQ has been administered to tens of thousands of persons in medical and surgical outpatient clinics, general hospital inpatients, psychiatric hospitals, sleep disorders centers, and university psychology departments. It has been translated into French, Dutch, German, Italian, Spanish, Greek, Arabic, and Turkish; therefore, there is a substantial pool of data available for secondary analysis if the above problems could be resolved. The rationale for the present study was to perform secondary analysis of new data to

reassess the factor structure of the 4 existing subscales via EFA. It was also hoped that new
subscales could be derived, such as a specific insomnia subscale. Finally, it was hoped to reduce
the total number of questions from 176 to a more manageable size for the SDQ-2 revision.

203

204 Methods:

In all, SDQ responses of 2185 adults (1543 males, 642 females) were obtained for secondary analysis from a variety of hospitals and universities at which the SDQ had been completed prior to a laboratory nocturnal polysomnogram Responses were gathered over the period 1986 – 2007, data collation was completed in 2008, and computer analysis took place from 2008-2011. These data therefore represented a sample of convenience and not a population

sample planned in advance. Since most of these sites were either psychiatric facilities or general 210 sleep disorders centers, the focus of the SDQ is necessarily slanted towards symptoms 211 experienced by such patients rather than the general population. Polysomnographic data are not 212 reported here but will be reported in future papers on subscale validation. 213 Of the above total, 1356 participants were patients of Dr. Douglass at various hospitals, 214 215 meaning that he was aware of their identities. The IRB allowed SDQs on these charts to be retrospectively reviewed with the proviso that their anonymity be ensured by assigning code 216 numbers as case identifiers, instead of patient names or hospital chart numbers, before being 217 218 included in the analysis. In the case of patients from other doctors or hospitals, code numbers were used exclusively. The data from 54 cases (2.5% of total) were discarded because more than 219 20% of items were unanswered, leaving the data of 2131 persons (1497 males, 634 females) for 220 221 the EFA. This gave a patient-to-questionnaire-item ratio of 12:1, which is commonly regarded as adequate for multivariate analysis. Any remaining missing values among the 176 items were 222 replaced by using a multiple imputation procedure ("PROC-MI", SAS version 9.1, SAS Institute, 223 Cary, North Carolina), which operates via an iterative process. This version of SAS software 224 was also used to compute the EFAs ("PROC-FACTOR") using a varimax factor rotation of both 225 226 orthogonal and oblique types. Eigenvalues and scree plots were used to determine the final 227 number of factors to be retained.

We then examined the items in each factor by condition index to determine if there was significant collinearity; if so, all but one of the collinear variables was deleted. After the main factors had been determined, a secondary factor analysis was run on some factors that proved to be heterogeneous, in order to identify possible subfactors.

The original SDQ had 9 gender-specific items (4 for males, 5 for females). We dealt with 232 these by removing all of them from the main factor analysis. We then split the file by sex and 233 analyzed the responses of males and females separately, after removing items from the opposite 234 sex. This also allowed us to verify whether the factor structure was similar in men and women. 235 More detailed explanations of the statistical methods and results are shown in the Supporting 236 237 Information section. Under an authorization dated 2008-04-11 by the University of Ottawa Social Sciences 238 and Humanities Research Ethics Board (File 02-08-16), secondary use of anonymized data from 239

the institutions listed in the attached "Thank-you Attestation" was approved. The project was

also approved in 2008 (File number 2008001) by the *Research Ethics Board of the Royal Ottawa*

242 Hospital.

243

Results:

Clinical and demographic details about the SDQ respondents are found in Table 1. Fiftyfour cases were deleted due to missing data, giving a case-wise missing rate of 2.5%. After deletions, the remaining variable-wise average missing rate was 3.1%, all of which were replaced by imputed values.

249

Table 1: Characteristics of the respondents $(n = 2185^{\circ})$.

	MALES				FEMALES		
		Mean				Mean	
DIAGNOSTIC GROUP	Ν	Age	SD		N	Age	SD
Psychiatric Patients ^a	574	45.18	13.41		296	41.85	12.67
General Practice Referrals ^b	899	45.23	13.77		338	44.78	13.79
Normal control subjects	70	38.70	12.71		8	38.61	12.73
SUBTOTALS	1543	44.92	13.59		642	43.35	13.27
Male + Female TOTAL				2185			

252	54 removed (missing data) 1497 2131 634
252 253 254 255	Table 1 Legend: ^a Hospital inpatients and outpatients with mood disorders, schizophrenia, anxiety disorders,
256	PTSD, or alcoholism. They were usually studied clinically to rule-out a possible physical sleep
257	disorder but some took part in research sleep studies (baseline nights). All patients were studied
258	without CPAP or other physical treatment for sleep apnea.
259	^b Patients with a medical / surgical diagnosis who were referred by their general practitioner or
260	specialist to rule out sleep apnea or physical causes of insomnia.
261	^c A total of 54 respondents (2.5% of total) were removed due to having \geq 20% missing items.
262	
263	The EFA revealed four Main Factors when using a visually-determined scree cutoff, all
264	of which had an eigenvalue > 5.0 (Fig. 1).
265	
266	
267	**** insert Fig. 1 about here ****
268	Fig. 1 Legend:
269	Scree Plot of all factors extracted by the EFA. The first 4 factors all have eigenvalues
270	greater than 5, and are referred to as Main Factors in the text.
271	
272	

273

274

The percentage of overall variance explained by these factors is shown in Table 2.

Table 2: Percentage of overall variance explained by the 4 Main Factors.

276

	Orthogonal R	Rotation	Obliqu	e Rotation
			Shared variance	Unique variance
1	12.76	5	15.43	8.92
2	8.89		11.53	6.69
3	6.68		8.67	5.91
4	6.57	7	6.46	6.43
OTAL	34.90)	42.09	27.95
able 2 Lo Factor nu	egend: mbers in the table	e refer to thos	e in Figure 1.	
able 3: I	nter-Correlation	s of the 4 Ma	ain Factors (Obli	que rotation).
able 3: I			ain Factors (Obli	que rotation).
	Factor1 Facto	or2 Factor3	Factor4	que rotation).
Factor1		or2 Factor3 64 0.189	Factor4 -0.021	que rotation).
Factor1 Factor2	Factor1 Facto	br2 Factor3 64 0.189 1 0.097	Factor4 -0.021 0.069	que rotation).
Factor1 Factor2 Factor3	Factor1 Facto	or2 Factor3 64 0.189	Factor4 -0.021 0.069 -0.091	que rotation).
Factor1 Factor2	Factor1 Facto	br2 Factor3 64 0.189 1 0.097	Factor4 -0.021 0.069	que rotation).
Factor1 Factor2 Factor3	Factor1 Facto 1 0.2	br2 Factor3 64 0.189 1 0.097	Factor4 -0.021 0.069 -0.091	que rotation).
Factor1 Factor2 Factor3 Factor4	Factor1 Facto 1 0.2	n2 Factor3 64 0.189 1 0.097 1	Factor4 -0.021 0.069 -0.091 1	que rotation). e of the Main Factors,

had been removed.

296 297 Secondary EFA of Main Factor 1 resulted in 3 subfactors with clinical relevance, while 298 299 the same process on Main Factor 2 resulted in 2 subfactors. Therefore, 7 useful factors were extracted from the SDQ data. Scree plots of the secondary EFAs for Main Factors 1 to 4 are 300 described in Figs. S1 -- S4. 301 Item loadings on the Main Factors and their subfactors are shown in Tables 4 - 7. In 302 these tables, items that were also present on the four original SDQ subscales are identified with 303 different markers. Items selected for the final SDO-2 subscales had to have item loadings of 0.4 304 or greater on the above factors. 305 Subscale homogeneity was calculated via Cronbach's alpha for each of the 7 subscales 306 307 and is shown below. Collinearity diagnostics on all factors are shown in S1 Appendix, along with the names of 308 items that were removed to resolve the collinearity. The number of items removed from Main 309 Factors 1 - 4 by this process were 0, 2, 1, and 2, respectively. 310 In addition to the four Main Factors, another 15 factors resulted from the primary EFA, 311 numbered 5 - 19, all with eigenvalues > 1. The subject matter of these factors and their item 312 loadings are summarized in S1 Table. While they do not uniquely identify any clinical sleep 313 disorders, they may be of interest to some readers considering the large pool of respondents in 314 this study. Examples of their content include: psychosomatic causes of insomnia; seizures and 315 parasomnias; tonsil and adenoid problems; and sleepiness due to shift work. 316 Below is a detailed description of the 7 factors identified above and their homogeneity 317 318 (Cronbach's alphas). These factors are proposed to be the subscales of the new SDQ-2.

319

320 Main Factor 1: Insomnia:

321 322	Subfactor 1A "InsPsy": Psychological features of insomnia ($\alpha = 0.919$) Subfactor 1B "InsSubj": Subjective description of insomnia severity ($\alpha = 0.831$)
323	Subfactor 1C "InsPLM": Insomnia due to leg sensations ($\alpha = 0.823$)
324	Subluctor resining and the institute of the sensations (a side of
325	
326	Table 4 lists items that load on Main Factor 1 using an orthogonal rotation. Results for
327	the oblique rotation were similar. This factor incorporates 5 items from the original SDQ-PSY
328	subscale (marked with " Ψ "), as well as 5 from the original SDQ-PLM subscale (marked with
329	"L"). Also shown are 7 of the SDQ items from Brower's 1998 insomnia subscale[37]. The
330	scree plot of the secondary factor analysis of Main Factor 1 (S1 Fig.) does not have a clear visual
331	cut-off but there are 3 factors having an eigenvalue ≥ 1 . When using an orthogonal rotation,
332	Subfactor 1A explained 6.1% of the overall dataset variance, subfactor 1B explained 5.6% and
333	subfactor 1C explained 2.8%. Subfactor 1A included psychological items such as "my sleep is
334	disturbed by worrying." Subfactor 1B is a subjective description of insomnia severity, with items
335	such as "I get too little sleep at night." The 4 items on Subfactor 1C describe limb movements
336	disturbing sleep.
337	

339

Table 4: Item loadings on each subfactor of Main Factor 1 (orthogonal rotation). 341 342

Item	1A	1 B	1C	Source ^a	Brief Item Description
34	0.801	0.187	0.173	-	sleep disturbed by worrying
8	0.787	0.121	0.172	-	worry about things at bedtime
33	0.761	0.169	0.196	Ψ	sleep disturbed by sadness or depression
7	0.737	0.116	0.195	Ψ	feel sad and depressed at bedtime
32	0.711	0.268	0.196	-	sleep disturbed by racing thoughts
6	0.681	0.201	0.129	Ψ	thoughts race through my mind at bedtime
10	0.625	0.398	0.176	-	afraid of not being able to go to sleep
36	0.587	0.370	0.183	-	being unable to get back to sleep if should wake
130	0.566	0.226	0.060	-	mental stress, worry, or anxiety worsens sleep
13	0.537	0.487	0.125	-	not able to get to sleep once awake at night
3	0.517	0.510	0.144	Ψ^*	have trouble getting to sleep at night
17	0.390	0.240	0.138	-	sleep is disturbed by noise
2	0.174	0.802	0.177	*	a poor night's sleep
87	0.169	0.761	0.182	*	problem with sleep
14	0.195	0.731	0.285	-	night sleep is restless and disturbed
1	0.209	0.714	0.097	*	too little sleep at night
44	0.121	0.707	0.180	*	feel that sleep is abnormal
4	0.132	0.685	0.185	L*	wake up often during the night
45	0.432	0.547	0.088	L*	respondent suspects they have insomnia
154	0.295	0.469	0.022	L	longest wake period at night
43	0.368	0.403	0.084	Ψ^*	been unable to sleep at all for several days
114	0.308	0.367	0.147	-	prescription hypnotics [kept due to face validity]
153	-0.263	-0.552	-0.040	-	hours of sleep at night [reverse coded on SDQ-2]
31	0.124	0.209	0.837	L	sleep disturbed by "restless legs"
12	0.151	0.207	0.808	L	have "restless legs" when falling asleep
35	0.323	0.167	0.678	-	sleep disturbed by muscular tension
9	0.370	0.183	0.632	-	muscular tension at bedtime

343

344 Legend for Table 4:

345 Subfactor loadings are shown in order of decreasing magnitude. Loadings in gray highlight

indicate factor loadings of 0.4 or greater that were selected as SDQ-2 scale items.

- 347 **Item:** Numerical label of this item on the original SDQ.
- 348 1A: Subfactor related to psychological causes of insomnia.

349	1B : Subfactor related to a subjective description of insomnia severity.
350	1C : Subfactor related to insomnia attributed to leg sensations.
351	*Source : Indicates item appeared on a subscale of the original SDQ, as follows:
352	L: SDQ-PLM subscale.
353	Ψ : SDQ-PSY subscale.
354	"*": Brower's insomnia subscale[37] that predicts alcoholism relapse.
355	"-": Was not a member of an SDQ subscale.
356	
357	
358	Items 17 ("sleep is disturbed by noise") and 114 ("use prescription hypnotics to sleep")
359	only approached criterion on subfactors A and B (loadings of 0.39 and 0.37 respectively) but will
360	be included in those subfactors due to face validity. Items 3, 13 and 45 co-load on both
361	subfactors A and B. Item 13 ("I fear not being able to get back to sleep after waking") will be
362	associated with subfactor 1A while item 3 ("trouble getting to sleep at night") and item 45
363	("suspect that I have insomnia") will be associated with subfactor 1B.
364	
365 366 367 368	Main Factor 2: Narcolepsy and Daytime Sleepiness Subfactor 2A "EDS": Excessive Daytime Sleepiness (α = 0.827) Subfactor 2B "NAR": Narcolepsy symptoms (α = 0.829)
369	Table 5 lists items that have a loading of 0.4 or higher on either the orthogonal or oblique
370	rotations on this factor. Main Factor 2 incorporates 13 of the 15 items from the original SDQ-
371	NAR (narcolepsy) subscale, which are marked with "#".
372 373	

6					
	Item	2A	2B	Source	Brief Item Description
	55	0.834	0.149	#	very sleepy during the day, struggle to stay awake
	41	0.714	0.101	-	sometimes very sleepy in the daytime, in cycles
	58	0.700	0.201	#	trouble doing job because of sleepiness / fatigue
	59	0.652	0.176	#	too sleepy to drive
	56	0.599	0.144	#	fall asleep eating, on phone, in bus, TV, reading, etc.
	42	0.582	0.272	#	have slept/been sleepy for several days at a time
	158	0.518	0.136	-	number of daytime naps
	157	0.467	0.215	-	car accidents due to sleepiness
	91	0.429	0.100	-	sleeping more than previously
	115	0.281	0.280	-	prescription drug to stay awake in day
	161	-0.290	-0.042	-	refreshed for how long after day nap
	39	0.415	0.743	#	Feel paralyzed after a nap
	60	0.126	0.681	#	hallucinations before/after nap while awake
	11	0.034	0.661	#	paralyzed when falling asleep
	40	0.047	0.657	#	hallucinations after waking in the morning
	67	0.243	0.617	#	sudden muscular weakness with strong emotions
	61	0.228	0.595	-	vivid dreams during naps
	66	0.193	0.585	#	"weak knees" when laughing
	64	0.313	0.495	-	nonsense behaviour
	63	0.330	0.446	#	driven car to wrong place, can't remember how
	57	0.316	0.357	#	bad grades in school because of sleepiness
	156	0.255	0.260	-	work accidents due to sleepiness

Table 5: Item loadings on each subfactor of Main Factor 2 (orthogonal rotation).

376

377

378 Legend for Table 5:

- 379 Item: Numerical label of this item on the original SDQ;
- **380 2A**: Subfactor related to excessive daytime sleepiness;
- **381 2B**: Subfactor related to neurological symptoms of narcolepsy;
- **Source**: This item appeared on a subscale of the original SDQ, as follows:
- 383 "#": SDQ-NAR subscale
- 384 "-": Was not a member of an SDQ subscale.

386	The scree plot (S2 Fig.) from the secondary factor analysis on Main Factor 2 showed a					
387	clear visual cut-off point after the second factor. Subfactor 2A explained 4.9% of the overall					
388	dataset variance and included items that describe subjective daytime sleepiness from any cause					
389	("I am some	etimes too	sleepy to	drive").	Subfactor 2B explained 4.6% of the overall variance and	
390	describes cl	assical syr	nptoms c	of narcoler	osy ("I am paralyzed when falling asleep").	
391	No i	tems co-lo	aded ont	to the two	subfactors. SDQ items 115, 161, and 156 did not load	
392	significantly	onto eith	er subfac	tor, nor o	n the main factor and so will be omitted.	
393						
394	Main Fac	tor 3: Si	ıbstanc	es Affec	ting Sleep ("SUBST"), $\alpha = 0.685$	
395	This	factor con	ncerns pe	rsons who	o report substance use or abuse and its effect on sleep.	
396	Table 6 lists	the items	that hav	e a loading	g of 0.4 or higher on this factor, on either the orthogonal	
397	or oblique r	otations. F	actor 3 b	ears no re	elation to any subscale of the original SDQ.	
398						
399 400 401	======================================	em loadin	igs on ea	ch subfac	etor of Main Factor 3 (orthogonal rotation).	
	Item	3 A	3B	Source	Brief Item Description	
	105	0.773	0.063	-	use alcohol in order to get to sleep	
	111	0.698	0.059	-	used marijuana to help get to sleep	
	109	0.698	0.102	-	used "street drugs"	
	107	0.697	0.100	-	unaware of actions when drinking	
	110	0.637	0.044	-	used tobacco to help get to sleep tobacco within 2 hours of bedtime	
	108 165	0.633	0.055 0.861	-	weight at age 20	
	163	0.023 0.071	0.801	-	height	
	1/2	0.0/1	0.031		norgin	

402

403 Legend for Table 6:

Gender

-0.158

404 Main Factor 3 relates to subjective sleep difficulties related to substance use or abuse.

405 Item: Numerical label of this item on the original SDQ.

-0.821

1 = male, 2 = female

406	3A, 3B: Sub-factorizations of Main Factor 3. Items on 3B <i>were not kept</i> for SDQ-2
407	Source : None of these items appeared on any subscale of the original SDQ.
408	
409	We performed a secondary factor analysis on this third factor to determine if it was
410	homogenous. The scree plot (S3 Fig.) shows a clear visual cut-off after the second factor,
411	eigenvalue >1. Subfactor 3A explains 3.5% of the overall dataset variance while subfactor 3B
412	explains 2.1%. Subfactor 3A included all of this subfactor's items except 3 that are linked to
413	males: gender, item 172 (height), and item 165 (weight at age 20). It seems likely that the last
414	two items are included due to collinearity with the gender item and are not linked to substance
415	use, so they will not be considered legitimate items for this subfactor. Therefore, only gender
416	will be retained, and on a unitary factor 3.
417	
418	Main Factor 4: Sleep Disordered Breathing ("SDB"), $\alpha = 0.762$
419	This factor incorporated 10 of the 12 items from the original SDQ-SA subscale (marked

with "@" in Table 7). This table also lists the items that have a loading of 0.4 or higher on this
factor, in either orthogonal or oblique rotations.

423

424 Table 7: Item loadings on each subfactor of Main Factor 4 (orthogonal rotation).

425

426

Item	4	4 A	4B	Source	Brief Item Description
21	0.744	0.757	0.320	(a)	snore loudly and bother others
141	0.631	0.711	0.172	(a)	snoring / breathing problem worse on back
22	0.654	0.672	0.243	(a)	stop breathing in sleep
143	0.373	0.611	0.058	-	snoring / breathing worse with allergy / infection
23	0.479	0.572	0.111	(a)	awake suddenly gasping for breath
15	0.463	0.559	0.110	-	sleep disturbs bed partner's sleep
139	0.330	0.511	-0.054	-	nose blocking up when trying to sleep
142	0.409	0.486	0.136	(a)	snoring / breathing problem worse after alcohol
173	0.416	0.309	0.136	(a)	age
71	0.390	0.283	0.250	(a)	high blood pressure [retained for face validity]
163	0.722	0.213	0.918	(a)	current weight
165	0.504	0.018	0.794	-	what was your weight at age 20
172	0.636	0.245	0.751	(a)	how tall are you
144	0.440	0.405		-	completed menopause? 1=no 5=agree strongly
"176"	0.636	0.245	0.641	@	available via "look-up matrix" using 163 & 172

427

428 Legend for Table 7:

429	Item:	Numerical label of this item on the original SDQ;
430	4:	Main Factor 4, prior to factoring into 4A and 4B. However, after consideration
431	of weigh	ht questions (see discussion in the text), Factor 4 was retained in its entirety
432	4A :	Subfactor related to symptoms of sleep disordered breathing
433	4B :	Subfactor related to weight, weight gain, and height
434	Source:	If marked "@", item was on the SA (sleep apnea) subscale of the original SDQ
435	If mar	ked "-", item did not appear on any subscale in the original SDQ.
436		
437	We perf	formed a secondary factor analysis on Factor 4 to determine if it was
438	homogenous.	The scree plot (S4 Fig.) shows two factors with an eigenvalue > 1 . Using an
439	orthogonal rota	tion, subfactor 4A explained 4.1% of the overall dataset variance while subfactor

4B explained 3.6% of the variance. Results for the oblique rotation were not much different. 440 Subfactor 4A contains items pertaining to breathing difficulties such as "I snore." Subfactor 4B 441 contains items concerning gender and weight. Since 4B items also have face validity for an 442 apnea scale, Main Factor 4 will therefore be regarded as unitary. Item 18 ("I suffer from 443 heartburn and choking") did not significantly load on either subfactor nor does it significantly 444 445 load on the main factor, so does not merit inclusion in SDQ-2. It is worth noting that items "weight at age 20" and "weight 6 months ago" were 446 originally included in the SDQ in order to investigate the observation by some sleep medicine 447 professionals that apnea patients tend to gain weight over time, often rapidly. Therefore, two new 448 variables "weight gained in the past 6 months" and "weight gained since age 20" were calculated 449 from existing items. The former did not load significantly on any factor, but "weight gain since 450

451 age 20" loaded onto Factor 4 with weight 0.56. The latter has been drafted as a new item for

452 SDQ-2.

Item 144 ("I have gone through the menopause") will be used only in the female version of the SDQ-2's SDB subscale, which will therefore be one item longer than the male version. Item 172 ("How tall are you?") has been retained on this subscale, since Item 176 (BMI) will not be specifically asked about on the SDQ-2. Rather, a 5 x 5 cell look-up table (see S2 Table) comprised of items 172 (height) and 163 (weight) will be supplied to users to allow them to make an approximate calculation of BMI if this is desired.

459

460 **Factor Analyses by Gender**

Gender items were first removed from the dataset, after which it was split into male and
female datasets. Separate factor analyses performed on the latter produced similar factor

structures and item loadings. Interestingly, subfactors 2A and 2B (narcolepsy and daytime 463 sleepiness) came out as their own factors in both the male and female datasets, as opposed to 464 being subfactors of a Main Factor in the combined dataset. The other factors in the gender-based 465 analysis did not differ markedly from those in the combined data set. 466 When the gender-related items were put back into the split analyses, none of the four 467 468 items for men loaded significantly on any of the main factors. They did load onto their own separate factor which could be considered a subscale of erectile dysfunction, but these items will 469 not be included as a separate subscale on the SDQ-2. 470

471

472 **DISCUSSION:**

This EFA of the original 176-item SDQ succeeded in its goals. It confirmed and resolved problems with the 4 subscales of the original SDQ, notably their conflation of general daytime sleepiness with neurological symptoms of narcolepsy, and a similar conflation of psychiatric insomnia symptoms with those of simple insomnia disorder. These problems were the result of the limitations of the original discriminant function analysis, so the superiority of EFA on these data is therefore confirmed. In addition, the new factors extracted comprised only 66 items,

allowing SDQ-2 to be much quicker to administer than the original questionnaire.

The end result of this analysis is the creation of a new questionnaire, the SDQ-2, whose subscales will consist of the items on the 7 factors described above. These new subscales will be named: *InsPsy* (psychological features of insomnia), *InsSubj* (subjective estimate of insomnia severity), *InsPLM* (insomnia due to limb movements), *EDS* (excessive daytime sleepiness), *NAR* (neurological symptoms of narcolepsy), *SUBST* (sleep effects of substance use), and *SDB* (sleepdisordered breathing). The fact that a similar factor structure emerged when the dataset was

divided into male and female respondents suggests that SDQ-2 may evaluate men and women 486 equally well, although different cut-off scores indicative of the threshold of pathology will likely 487 be needed for each gender, as on the original SDQ. On Main Factor 2, SDQ's conflation of two 488 narcolepsy symptom domains - excessive daytime sleepiness and neurological symptoms of 489 narcolepsy -- was resolved by extracting subfactors 2A and 2B. Creation of the EDS subscale 490 491 also resolved another problem with the original SDQ: it had confounded some of these items within its PLM and PSY subscales. In effect, InsPSY replaces the original PSY subscale, while 492 InsPLM replaces the original PLM scale. The new NAR scale fully replaces the original NAR 493 494 scale and is now much more specific for the neurological symptoms and signs of narcolepsy, while the new EDS scale independently evaluates sleepiness from whatever cause. 495

The SDB subscale contained 10 of the 12 original items from the SDQ-SA subscale. While it had two subfactors, breathing difficulties and obesity, having a subscale consisting entirely of weight-related questions was not thought to be useful, so these items were included in Factor 4 to produce a unitary SDB subscale. Although BMI is no longer an item on SDQ-2, its statistical contribution to the SDB scale is preserved by the 5-level height and weight items. For those users wishing to have a numerical estimate of BMI, the look-up matrix using these two items is shown in S2 Table.

503 An assessment of weight gain on the original SDQ required a clinician to perform 504 calculations using items "current weight" and "weight at age 20". This task will be replaced on 505 SDQ-2 by a new item that asks the patient directly how much weight (if any) they have gained 506 since they were 20 years old; this new item loads on the SDB scale.

507 Of the five SDQ questions for women, only item 144 "I have gone through the 508 menopause" loaded significantly onto any of the 7 factors -- SDB. There is some evidence[41]

that lower estrogen levels after menopause cause a lessening of muscle tone, which might
aggravate sleep apnea, so this item will be included in the SDQ-2. The other gender-related
questions will be discarded.

Being shorter than the original SDQ, the SDQ-2 is expected to have a higher completion rate among patients and to be quicker to complete. As noted above, the 7 new subscales should resolve the original SDQ's inadvertent over-diagnosis of narcolepsy and psychiatric features of insomnia, as identified by Schwegler[8]. The new insomnia subscales also validate the work of Schweer[40] and Brower[37] who proposed insomnia subscales made up of existing SDQ items. In fact, 13 of the 16 items on Sweere's *Insomnia* scale appear on Main Factor 1 in the present study.

Nevertheless, there are some cautionary notes. The sample of SDQ respondents upon which the present study is based was not a random population sample. Most were either referred to sleep disorder clinics with a suspected sleep disorder or were patients with another known disorder that was suspected of causing sleep-wake symptoms, i.e., depression, schizophrenia, alcoholism, chronic fatigue syndrome, or general medical illness. Other respondents were normal university students in psychology courses or healthy control participants in clinical research studies.

In this retrospective dataset, there were no structured interview diagnoses of respondents' sleep disorders, psychiatric illnesses, or general medical conditions. Likewise, no racial / ethnic / cultural information was available. Although some clinical diagnoses unrelated to sleep were available, these were made by numerous clinicians in different hospitals in different years and without uniform diagnostic criteria.

Another caution is that the data upon which the current study is based were collected over a long time span, some being almost 35 years old. During this interval there were changes in clinical nosology and polysomnographic measurement techniques, not to mention cultural and linguistic changes. It is therefore possible that the response set of the respondents was not homogeneous, introducing further error variance. On the positive side, such issues would, again, be somewhat mitigated by the large sample size.

The present paper does not show any validation of the new subscales, although most of 537 the respondents had polysomnography. In fact, only 78 persons in this study were normal 538 539 controls who had no sleep complaints but even they were not age-matched to patients and did not have polysomnography. Therefore, the factor structure reported here needs to be confirmed in 540 larger samples, hopefully including normal persons age-matched to polysomnographically-541 diagnosed patients. In future validation studies, an ROC analysis of each SDQ-2 subscale will be 542 very informative and will likely find different cut-off scores in men versus women to indicate the 543 544 threshold for pathology.

Previous studies of the original SDQ-SA subscale by other authors -- using patients that
were not included in the present study -- have shown its accurate identification of sleep apnea.
Hopefully, future convergent and divergent validity studies of the new SDQ-2 subscales using
psychometric and physiological assessments will show even greater precision.

The 7 subscales proposed in the present article will allow re-analysis of SDQ datasets gathered by different investigators over the years; these contain the responses of tens of thousands of persons. Especially in those datasets from controlled studies of PTSD, CFS, depression, and anxiety, it is possible that new insights into those patients' symptoms could be obtained via these new subscales.

It should be noted that all of the subscales extracted by EFA in this article are based on 554 the exact wording and item-numbering of the original SDQ. It is for this reason that 555 retrospective analyses can be done on old SDQ data. However, on the new SDQ-2 questionnaire 556 there will be substantial changes in item-numbering plus a change in the form of Likert response 557 choices: from 1 ... 5 on the original SDQ to 0 ... 4 on the SDQ-2. There will also be re-558 559 wording of several items to give greater precision in symptom description, plus a general rewording to avoid adjectives about magnitude or intensity in the items' stems. For those users 560 wishing to continue using the original SDQ, it is suggested that the 4 original subscales be retired 561 562 in favour of the 7 new ones. For those users of the new 66-item SDQ-2, it will only be possible to score it by using the 7 new scales. 563

Future goals for the SDQ-2 include studies of test-retest reliability plus validity studies using other questionnaires and physiological measures. It is hoped that these will be done both in the original English version and in the translated versions, which in some cases would be the first validation of those translations. Such validation would facilitate comparison studies between occupational, cultural, linguistic, and geographical groups.

A prospective study of 800 members of a large urban police force has been completed, in which the 7 new SDQ-2 subscales were concurrently validated against a number of published sleep and psychological questionnaires: ESS[9], ISI[42], STOP-Bang[15], Berlin Questionnaire[14], GAD-7[43], PHQ-9[44], MIES[45], PCL-5[46], and CAGE[47]. A

573 manuscript on this subject is in preparation.

The new SDQ-2 should have more clinical utility than the original SDQ, in that it identifies a greater range of sleep pathologies and does it with better precision. It may also supplant various shorter single-disorder questionnaires.

- 577 SDQ-2 will be available for distribution from the University of Ottawa's Institute of
- 578 Mental Health Research at the Royal (<u>https://www.theroyal.ca/research/sleep-mental-health-</u>
- 579 <u>research</u>). Technical questions can be sent by email to Dr. Douglass.

581

582 Author Contributions

- 583 Conceptualization: Alan Douglass, Kathleen Biard
- 584 Data Curation: Kathleen Biard, Alan Douglass,
- 585 Formal Analysis: Kathleen Biard, Alan Douglass,
- 586 Methodology: Alan Douglass, Kathleen Biard, Joseph De Koninck
- 587 Project Administration: Alan Douglass, Joseph De Koninck
- 588 Supervision: Alan Douglass, Joseph De Koninck
- 589 Writing original draft: Alan Douglass, Kathleen Biard
- 590 Writing review and editing: Alan Douglass, Kathleen Biard, Joseph De Koninck

591

593 Acknowledgements

594	Sleep Disorders Clinic, Royal Ottawa Mental Health Center (Drs. Alan Douglass, Elliott Lee,
595	and Louis Soucy) and The University of Ottawa Institute of Mental Health Research at the
596	Royal, Ottawa, Ontario, Canada
597	
598	University of Michigan Psychiatry Department (Drs. John Greden, Mark Demitrack, Israel
599	Liberzon, Kirk Brower, Alan Douglass) and Neurology Sleep Disorders Clinic (Drs. Michael
600	Aldrich, Ronald Chervin), UM Medical Center, Ann Arbor, Michigan, USA
601	
602	Sleep Disorders Center, Stanford University Medical Center (Drs. Christian Guilleminault,
603	William C. Dement, Sharon Keenan RPsgT), Palo Alto, California, USA.
604	
605	Sleep Disorders Clinic, University of Alberta Hospital (Drs. Alan Douglass and Godfrey Man;
606	Rhoda Schreiner RPsgT), Edmonton, AB, Canada.
607	
608	Psychology Dept., University of Alberta (Dr. Don Kuiken), Edmonton, AB, Canada
609	
610	Harborview Medical Center, University of Washington (Dr. Dedra Buchwald), Seattle,
611	Washington, USA
612	
613	Sleep Disorders Clinic, Isaac Walton Killam Hospital, Dalhousie University (Dr. Rachel
614	Moorehouse), Halifax, Nova Scotia, Canada.
615	

616 **References**

617	1.	Douglass AB, Bornstein R, Nino-Murcia G, Keenan S, Miles L, Zarcone VPJ, et al. The
618	Sleep	Disorders Questionnaire. I: Creation and multivariate structure of SDQ. Sleep.
619	1994;	17(2):160-7.
620		
621	2.	Miles LE. The Sleep Questionnaire and Assessment of Wakefulness. In: Guilleminault C,
622	editor	. Sleeping and waking disorders, indications and techniques. Menlo Park, CA: Addison-
623	Wesle	y Pub. Co. Medical/Nursing Division: 1982. p. 383–413.
624		
625	3.	Douglass AB. Item test-retest reliability of the Sleep Disorders Questionnaire (SDQ).
626	Sleep	Research. 1990;19:215.
627		
628	4.	Buysse DJ, Reynolds Cd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep
629	Qualit	y Index: a new instrument for psychiatric practice and research. Psychiatry Res.
630	1989;2	28(2):193-213.
631		
632	5.	Guichard K, Marti-Soler H, Micoulaud-Franchi JA, Philip P, Marques-Vidal P,
633	Voller	nweider P, et al. The NoSAS score: A new and simple screening tool for obstructive sleep
634	apnea	syndrome in depressive disorder. J Affect Disord. 2018;227:136-40.
635		
636	6.	Valipour A, Lavie P, Lothaller H, Mikulic I, Burghuber OC. Sleep profile and symptoms
637	of slee	ep disorders in patients with stable mild to moderate chronic obstructive pulmonary
638	diseas	e. Sleep Med. 2011;12(4):367-72.

|--|

640	7.	Valipour A, Lothaller H, Rauscher H, Zwick H, Burghuber OC, Lavie P. Gender-related
641	differe	nces in symptoms of patients with suspected breathing disorders in sleep: a clinical
642	popula	tion study using the sleep disorders questionnaire. Sleep. 2007;30(3):312-9.
643		
644	8.	Schwegler K, Klaghofer R, Nirrko AC, Mathis J, Hersberger KE, Bloch KE. Sleep and
645	wakefi	Iness disturbances in Swiss pharmacy customers. Swiss Medical Weekly. 2006;136(9-
646	10):14	9-54.
647		
648	9.	Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness
649	Scale.	Sleep. 1991;14(6):540-5.
650		
651	10.	Valencia-Flores M, Resendiz M, Castano VA, Santiago V, Campos RM, Sandino S, et al.
652	Object	ive and subjective sleep disturbances in patients with systemic lupus erythematosus.
653	Arthrit	is And Rheumatism. 1999;42(10):2189-93.
654		
655	11.	McCurry SM, Gibbons LE, Logsdon RG, Vitiello MV, Teri L. Nighttime insomnia
656	treatme	ent and education for Alzheimer's disease: A randomized, controlled trial. Journal of the
657	Amerio	can Geriatrics Society. 2005;53(5):793-802.
658		
659	12.	Longstreth WT, Koepsell TD, Ton TG, Hendrickson AF, Van Belle G. The epidemiology
660	of narc	olepsy. Sleep. 2007;30(1):13-26.
661		

662	13.	Happe S, Schrodl B, Faltl M, Muller C, Auff E, Zeitlhofer J. Sleep disorders and
663	depres	sion in patients with Parkinson's disease. Acta Neurol Scand. 2001;104(5):275-80.
664		
665	14.	Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire
666	to iden	tify patients at risk for the sleep apnea syndrome. Annals of Internal Medicine.
667	1999;1	31:485-91.
668		
669	15.	Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, et al. STOP
670	questic	onnaire - A tool to screen patients for obstructive sleep apnea. Anesthesiology.
671	2008;1	08(5):812-21.
672		
673	16.	Marti-Soler H, Hirotsu C, Marques-Vidal P, Vollenweider P, Waeber G, Preisig M, et al.
674	The No	oSAS score for screening of sleep-disordered breathing: a derivation and validation study.
675	Lancet	Respir Med. 2016;4(9):742-8.
676		
677	17.	Chai-Coetzer CL, Antic NA, Rowland LS, Catcheside PG, Esterman A, Reed RL, et al. A
678	simplif	fied model of screening questionnaire and home monitoring for obstructive sleep apnoea in
679	primar	y care. Thorax. 2011;66(3):213-9.
680		
681	18.	Schotland HM, Georeno AM, Pack AI. Obstructive sleep apnea: feasibility of a disease
682	manag	ement strategy utilizing primary care case finding. Journal of Clinical Outcomes
683	Manag	ement. 2000;7(7):34-8.
684		

685	19.	Chihorek AM, Abou-Khalil B, Malow BA. Obstructive sleep apnea is associated with
686	seizure	e occurrence in older adults with epilepsy. Neurology. 2007;69(19):1823-7.
687		
688	20.	Lancaster LH, Mason WR, Parnell JA, Rice TW, Lloyd JE, Milstone AP, et al.
689	Obstru	ctive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. 2009;136(3):772-8.
690		
691	21.	Abrishami A, Khajehdehi A, Chung F. A systematic review of screening questionnaires
692	for obs	structive sleep apnea. Canadian Journal of Anaesthesia-Journal Canadien D'Anesthesie.
693	2010;5	7(5):423-38.
694		
695	22.	Chervin RD. Use of clinical tools and tests in sleep medicine. In: Kryger MH, Roth T,
696	Demer	nt WC, editors. Principles and Practice of Sleep Medicine, 3 ed. Philadelphia: W. B.
697	Saunde	ers; 2000. p. 535-46.
698		
699	23.	Ramachandran SK, Josephs LA. A meta-analysis of clinical screening tests for
700	obstrue	ctive sleep apnea. Anesthesiology. 2009;110(4):928-39.
701		
702	24.	See the IW, Wilding JP. Screening for obstructive sleep apnoea in obesity and diabetes
703	potenti	al for future approaches. Eur J Clin Invest. 2013;43(6):640-55.
704		
705		

706	25.	Economou NT, Dikeos D, Andrews N, Foldvary-Schaefer N. Use of the Sleep Apnea
707	Scale of	of the Sleep Disorders Questionnaire (SA-SDQ) in adults with epilepsy. Epilepsy Behav.
708	2014;3	1:123-6.
709		
710	26.	Klingman KJ, Jungquist CR, Perlis ML. Questionnaires that screen for multiple sleep
711	disorde	ers. Sleep Med Rev. 2017;32:37-44.
712		
713	27.	Lichtblau M, Bratton D, Giroud P, Weiler T, Bloch KE, Brack T. Risk of sleepiness-
714	related	accidents in Switzerland: results of an online sleep apnea risk questionnaire and
715	awarer	ness campaigns. Front Med (Lausanne). 2017;4:34.
716		
717	28.	Malow BA, Bowes RJ, Lin X. Predictors of sleepiness in epilepsy patients. Sleep.
718	1997;2	0(12):1105-10.
719		
720	29.	Weatherwax KJ, Malow BA. The use of the Sleep Apnea Scale of the Sleep Disorders
721	Questi	onnaire in patients with epilepsy. Sleep. 2003;26:A223.
722		
723	30.	Bassetti C, Aldrich MS, Chervin RD, Quint D. Sleep apnea in patients with transient
724	ischem	tic attack and stroke: a prospective study of 59 patients. Neurology. 1996;47(5):1167-73.
725		
726	31.	Sacco RL. Risk factors and outcomes for ischemic stroke. Neurology. 1995;45(2 Suppl
727	1):S10	-4.
728		

729	32.	Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med.
730	1995;3	33(21):1392-400.
731		
732	33.	Bassetti C, Aldrich MS, Quint D. Sleep-disordered breathing in patients with acute supra-
733	and inf	ratentorial strokes. A prospective study of 39 patients. Stroke. 1997;28(9):1765-72.
734		
735	34.	Valencia-Flores M, Orea A, Castano VA, Resendiz M, Rosales M. Prevalence of sleep
736	apnea a	and electrocardiographic disturbances in morbidly obese patients. Obesity Res.
737	2000;8	(3):262-9.
738		
739	35.	Douglass AB. Validation of the "Psych" scale of the Sleep Disorders Questionnaire
740	(SDQ)	Sleep Research. 1992;21:150.
741		
742	36.	Carroll BJ, Feinberg M, Smouse PE, Rawson SG, Greden JF. The Carroll Rating Scale
743	for Dep	pression I: development, reliability, and validation. British Journal of Psychiatry.
744	1981;1	38(3):194-200.
745		
746	37.	Brower KJ, Aldrich MS, Hall JM. Polysomnographic and subjective sleep predictors of
747	alcoho	ic relapse. Alcohol Clin Exp Res. 1998;22(8):1864-71.
748		
749	38.	Smith S, Trinder J. Detecting insomnia: comparison of four self-report measures of sleep
750	in a yo	ung adult population. Journal Of Sleep Research. 2001;10(3):229-35.
751		

752	39.	Chesson A, Jr., Hartse K, Anderson WM, Davila D, Johnson S, Littner M, et al. Practice
753	parame	eters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine
754	report.	Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep.
755	2000;2	3(2):237-41.
756		
757	40.	Sweere Y, Kerkhof GA, De Weerd AW, Kamphuisen HAC, Kemp B, Schimsheimer RJ.
758	The va	lidity of the Dutch Sleep Disorders Questionnaire (SDQ). J Psychosom Res.
759	1998;4	5(6):549-55.
760		
761	41.	Perger E, Mattaliano P, Lombardi C. Menopause and sleep apnea. Maturitas.
762	2019;1	24:35-8.
763		
764	42.	Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index:
765	psycho	metric indicators to detect insomnia cases and evaluate treatment response. Sleep.
766	2011;3	4(5):601-8.
767		
768	43.	Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized
769	anxiety	v disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-7.
770		
771	44.	Martin A, Rief W, Klaiberg A, Braehler E. Validity of the Brief Patient Health
772	Questi	onnaire mood scale (PHQ-9) in the general population. Gen Hosp Psychiatry.
773	2006;2	8(1):71-7.
774		

775	45.	Nash WP, Marino Carper TL, Mills MA, Au T, Goldsmith A, Litz BT. Psychometric
776	evalua	tion of the Moral Injury Events Scale. Mil Med. 2013;178(6):646-52.
777		
778	46.	Ashbaugh AR, Houle-Johnson S, Herbert C, El-Hage W, Brunet A. Psychometric

validation of the English and French versions of the Posttraumatic Stress Disorder Checklist for

780 DSM-5 (PCL-5). PLoS One. 2016;11(10):e0161645.

- 781
- 782 47. Nilssen O, Ries RK, Rivara FP, Gurney JG, Jurkovich GJ. The CAGE questionnaire and
- the Short Michigan Alcohol Screening Test in trauma patients: comparison of their correlations
- with biological alcohol markers. J Trauma. 1994;36(6):784-8.




Figure 1., Scree Plot